Tower Research Capital (TRC)’s Rubius Therapeutics, Inc RUBY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-25
| Closed | – | – | 6643 |
|
|
2023
Q1 | $0 | Hold |
25
| – | – | ﹤0.01% | 6666 |
|
|
2022
Q4 | $0 | Sell |
25
-16,523
| -100% | -$4.51K | ﹤0.01% | 6718 |
|
|
2022
Q3 | $7K | Buy |
16,548
+1,546
| +10% | +$1.16K | ﹤0.01% | 4970 |
|
|
2022
Q2 | $13K | Buy |
15,002
+14,255
| +1,908% | +$23.9K | ﹤0.01% | 4256 |
|
|
2022
Q1 | $4K | Sell |
747
-8,670
| -92% | -$55.1K | ﹤0.01% | 5311 |
|
|
2021
Q4 | $92K | Sell |
9,417
-88
| -0.9% | -$1.22K | ﹤0.01% | 2285 |
|
|
2021
Q3 | $170K | Buy |
9,505
+5,948
| +167% | +$129K | ﹤0.01% | 1964 |
|
|
2021
Q2 | $87K | Buy |
3,557
+255
| +8% | +$6.38K | ﹤0.01% | 2541 |
|
|
2021
Q1 | $87K | Sell |
3,302
-541
| -14% | -$7.9K | ﹤0.01% | 2697 |
|
|
2020
Q4 | $29K | Sell |
3,843
-30,497
| -89% | -$181K | ﹤0.01% | 3610 |
|
|
2020
Q3 | $172K | Buy |
34,340
+24,677
| +255% | +$131K | ﹤0.01% | 2708 |
|
|
2020
Q2 | $58K | Buy |
9,663
+9,075
| +1,543% | +$53.6K | ﹤0.01% | 2943 |
|
|
2020
Q1 | $3K | Sell |
588
-6,134
| -91% | -$45.6K | ﹤0.01% | 2515 |
|
|
2019
Q4 | $64K | Buy |
6,722
+5,826
| +650% | +$56.4K | 0.01% | 1190 |
|
|
2019
Q3 | $7K | Sell |
896
-3,382
| -79% | -$39.4K | ﹤0.01% | 3172 |
|
|
2019
Q2 | $67K | Buy |
+4,278
| New | +$69K | ﹤0.01% | 1417 |
|
|
2019
Q1 | – | Sell |
-1,377
| Closed | -$22K | – | 4475 |
|
|
2018
Q4 | $22K | Buy |
+1,377
| New | +$25.1K | ﹤0.01% | 1887 |
|
Tower Research Capital (TRC)'s RUBY Position: Q2 2023 in Review
Tower Research Capital (TRC) sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2023, closing a stake of 25 shares.
Tower Research Capital (TRC) first reported a position in RUBY in Q4 2018 and held it in 17 quarters. The position peaked at $172K in Q3 2020. 0 funds tracked by Wall St. Rank hold RUBY as of Q2 2023.
- Tower Research Capital (TRC) reported no remaining Rubius Therapeutics, Inc position as of Q2 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 25 Rubius Therapeutics, Inc shares in Q2 2023.
- Tower Research Capital (TRC) first reported a position in Rubius Therapeutics, Inc in Q4 2018 and held it in 17 quarters.
- Tower Research Capital (TRC)'s Rubius Therapeutics, Inc position peaked at $172K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.